Login to Your Account

FDA: CDx co-development calls for 'market-ready performance' diagnostic

By Mark McCarty
Regulatory Editor

Thursday, August 18, 2016

The FDA co-development draft guidance for companion diagnostics and their associated therapeutics tackled a largely novel area of regulatory science for the practice of 21st Century medicine, but a webinar clarified that a CDx need not be a market-ready test.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription